Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukemia Research Institute, have developed an innovative CAR-T cell ...

A new Brazilian-developed CAR-T cell therapy has shown extraordinary results in treating refractory CD30+ lymphoma, including ...

Phase-I trial of HSPCAR30 therapy shows 100% response and 50% remission in CD30+ lymphoma patients with no major side effects ...

In a Phase 1 clinical trial, a CAR T-cell therapy targeting the CD30 protein has been shown to promote the expansion of memory T cells, leading to durable responses and improved clinical outcomes in ...

Lymphoma begins when healthy cells in the lymphatic system change and grow out of control. Because of their expression of cell membrane receptor 30 (CD30), classical Hodgkin lymphoma is also referred ...

Hodgkin lymphoma and other CD30+ lymphomas have posed a significant challenge to the medical community, particularly in refractory or relapsed cases where conventional treatments have so far shown ...

In a phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma, a 100% overall response rate and a 50% complete remission rate were achieved, along ...